Completed PHASE1 INTERVENTIONAL 4-arm NCT05504746

A Phase I Study of SHEN26 Capsule in Healthy Participants

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SHEN26 Capsule in Healthy Participants

Sponsor: Shenzhen Kexing Pharmaceutical Co., Ltd.

Interventions SHEN26 capsule SHEN26 placebo

Updated 4 times since 2022 Last updated: Dec 14, 2022 Started: Aug 8, 2022 Primary completion: Dec 11, 2022 Completion: Dec 11, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy Participants, this trial is completed. The trial is conducted by Shenzhen Kexing Pharmaceutical Co., Ltd. and has accumulated 4 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Sep 2022 — Jan 2023 [monthly]

Recruiting PHASE1

First recorded

Aug 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shenzhen Kexing Pharmaceutical Co., Ltd.

Data source: Kexing Biopharm Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hefei, China